# Mugglehead Investment Magazine

> Investment and financial news coverage. Mugglehead Investment Magazine (Mugglehead, Mugglehead Media) is published in English by Mugglehead Media Corp. and covers mining, energy, technology, health, psychedelics, cannabis, and the listed companies in them.

## Sections

- [Mining](https://mugglehead.com/category/mining/): Gold, Silver, Lithium, Uranium, Copper, Rare Earths
- [Energy](https://mugglehead.com/category/alternative-energy/): Hydrogen, Uranium
- [Technology](https://mugglehead.com/category/technology/): Crypto/Blockchain, AI and Autonomy, Security, Driving
- [Health](https://mugglehead.com/category/medical-and-pharmaceutical/): Sleep, Health & Wellness
- [Psychedelics](https://mugglehead.com/category/psychedelics/)
- [Cannabis](https://mugglehead.com/category/cannabis/): CBD, Edibles, Extraction, Hemp, Organic, Outdoor, Policy

## Feeds and sitemaps

- [RSS feed](https://mugglehead.com/feed/): the 20 newest stories with their full text; every section has its own at its address plus feed/
- [Sitemap](https://mugglehead.com/sitemap.xml): every story, section and author
- [Google News sitemap](https://mugglehead.com/news-sitemap.xml): the stories of the last 48 hours

## About

- [About](https://mugglehead.com/about-us/)
- [Contact](https://mugglehead.com/contact/)
- [Advertise](https://mugglehead.com/advertise/)
- [Contribute](https://mugglehead.com/contribute/)
- [Newsletter](https://mugglehead.com/newsletter/)
- [All stories](https://mugglehead.com/articles/): the archive, newest first

## Latest stories

- [Bitdeer Technologies Group sells 288.4 BTC, has zero pure holdings](https://mugglehead.com/bitdeer-technologies-group-weekly-bitcoin-sales/): The Sept. 25 weekly update lists 288.1 BTC mined and zero net coins added; Friday's Nasdaq close predates the post.
- [Eaton agrees to acquire COL Group for €810M in European power deal](https://mugglehead.com/eaton-col-group-810m-european-power-acquisition/): COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.
- [Pharming Group says FDA accepts lower-dose Joenja sNDA for review](https://mugglehead.com/pharming-group-lower-dose-joenja-snda-fda-review/): The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.
- [Lode Gold Resources begins Frankfurt trading after $9.72M July placement](https://mugglehead.com/lode-gold-resources-frankfurt-trading-july-placement/): Its July placement issued 35.98 million shares and matching warrants, while the latest notice disclosed $334,577 in finder fees.
- [ČEZ unit ŠKODA JS wins Rolls-Royce SMR control rod drive contract](https://mugglehead.com/cez-skoda-js-rolls-royce-smr-control-rod-drives/): The Czech supplier must develop an SMR prototype before global deliveries; the current award's price and shipment date were not released.
- [Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older](https://mugglehead.com/mirum-pharmaceuticals-atebrioz-fop-fda-approval/): Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.
- [Eli Lilly and Company wins FDA pediatric Olumiant approval for severe alopecia](https://mugglehead.com/eli-lilly-olumiant-pediatric-severe-alopecia-fda-approval/): In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.
- [WISeKey expects October 2 merger and October 5 WISeQey trading](https://mugglehead.com/wisekey-october-2026-bvi-merger-wiseqey-trading/): The Swiss cybersecurity group expects Oct. 2 to be the last session for its existing ADSs and Class B shares before a planned WISeQey listing.
- [Nanexa AB shares jump 105% on Novo Nordisk drug-delivery licence](https://mugglehead.com/nanexa-ab-novo-nordisk-drug-delivery-licence/): The Swedish developer says the deal could bring up to €1.165B, but its published terms do not separate the upfront payment from later milestones.
- [Merck and Daiichi Sankyo withdraw ifinatamab deruxtecan BLA](https://mugglehead.com/merck-daiichi-sankyo-withdraw-ifinatamab-deruxtecan-bla/): The partners cited FDA discussions over Phase 2 evidence and kept a randomized Phase 3 lung cancer trial enrolling.
- [Goldgroup Mining raises US$122M, issues 33.38M units](https://mugglehead.com/goldgroup-mining-122m-private-placement-close/): The US$3.65 units carry half a warrant each, and Goldgroup has not assigned the proceeds to specific projects.
- [Rexel agrees to buy GCG at US$1.4B enterprise value](https://mugglehead.com/rexel-gcg-1-4b-enterprise-value-acquisition/): Rexel plans about €800M in cash and debt and may raise up to €500M in equity before a targeted 2026 year-end close.
- [Lundin Gold reports 204.26 g/t gold over 3.05m at Bonza Sur](https://mugglehead.com/lundin-gold-bonza-sur-204-26-gold/): The Quebrada Dorada discovery extends the known gold mineralized trend at Fruta del Norte beyond eight kilometres.
- [PG&E's Diablo Canyon vessel report meets NRC surveillance rules](https://mugglehead.com/pge-diablo-canyon-capsule-report-nrc-review/): NRC staff found a Unit 1 reactor-vessel report met federal requirements on Sept. 24, months after renewing the plant's operating licences.
- [Akamai signs US$11.6B Anthropic cloud deal with US$5.5B buildout](https://mugglehead.com/akamai-anthropic-11-6b-cpu-cloud-agreement/): The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.
- [REGENXBIO reports three-year retinopathy improvement in 6 of 10](https://mugglehead.com/regenxbio-altitude-three-year-retinopathy-data/): The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.
- [Cresco Labs puts three restructuring resolutions to October 30 vote](https://mugglehead.com/cresco-labs-october-2026-restructuring-vote/): Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.
- [Clearmind Medicine reports three published US patent applications](https://mugglehead.com/clearmind-medicine-us-drug-combination-patent-applications/): The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.
- [Williams seeks FERC approval for US$54.7M Leidy gas expansion](https://mugglehead.com/williams-transco-leidy-access-expansion-ferc-notice/): A Sept. 24 federal notice opens intervention in Transco's Pennsylvania pipeline application, while Williams targets late 2027 service.
- [New York anti-inversion bill awaits Hochul after Curaleaf ad](https://mugglehead.com/new-york-anti-inversion-bill-curaleaf-hochul/): Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.
- [Cycurion expects US$843K in 2026 public-safety revenue](https://mugglehead.com/cycurion-843k-public-safety-revenue-2026/): A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.
- [Nextech3D.ai reports $1M-plus in new customer contracts](https://mugglehead.com/nextech3d-ai-1m-new-customer-contracts/): It counted 180 new customer contracts through Sept. 23 but gave no schedule for recognizing their value as revenue.
- [SLB wins four Aramco well contracts covering more than 450 wells](https://mugglehead.com/slb-aramco-450-wells-three-year-contracts/): The three-year Saudi program can run two years longer, but SLB did not disclose a contract value or a first-well date.
- [BlackBerry revenue rises 26% as QNX and licensing lift fiscal Q2](https://mugglehead.com/blackberry-q2-fiscal-2027-qnx-licensing-revenue/): Adjusted EPS beat BlackBerry's June outlook, while the company forecast a sharp licensing revenue decline in the next quarter.
- [Merck says remigromig met BRUNELLO vision endpoint, flags eye risks](https://mugglehead.com/merck-remigromig-brunello-vision-safety/): Both doses passed a vision noninferiority test against ranibizumab; higher rates of retinal complications await detail.
- [Jaguar Uranium finds up to 3,570 ppm rare earth oxides in Berlin core](https://mugglehead.com/jaguar-uranium-berlin-rare-earth-core-assays/): Selected historic core from Colombia also held magnet rare earth oxides, but continuity and recovery remain untested.
- [F3 Uranium names McElroy CEO, proposes share consolidation](https://mugglehead.com/f3-uranium-mcelroy-ceo-share-consolidation/): The 1-for-10 plan has shareholder approval but still needs TSX Venture Exchange acceptance; Dev Randhawa becomes executive chair.
- [aTyr Pharma says FDA aligned on 372-patient sarcoidosis trial](https://mugglehead.com/atyr-pharma-fda-alignment-sarcoidosis-phase-3/): The new Phase 3 study shifts its primary measure to lung function after an earlier miss, but aTyr says it needs more money to run it.
- [Sequans ends bitcoin treasury after sale of last 314 coins](https://mugglehead.com/sequans-sells-remaining-bitcoin-treasury-exit/): The company gave no sale proceeds or new cash balance, leaving its June 30 cash of US$21.0 million as the latest figure disclosed in the releases.
- [Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss](https://mugglehead.com/gossamer-bio-seralutinib-nda-pah-fda/): The FDA will decide whether to file the application for review after PROSERA's walking-distance gain missed its preset statistical cutoff.

## Optional

- [Privacy policy](https://mugglehead.com/privacy-policy/)
- [Terms of use](https://mugglehead.com/terms-of-use/)